# Brenetafusp

Source: https://onco.cc/drugs/brenetafusp/  
OnCo record `brenetafusp` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Brenetafusp is a soluble T-cell receptor bispecific, tebentafusp's successor, that recognises a PRAME peptide on HLA-A*02:01 and drags T cells onto the tumour. A phase 3 with nivolumab in first-line melanoma is enrolling, but only patients carrying HLA-A*02:01, about half of those of European ancestry, are eligible.

## Summary

Phase 1/2 in heavily pretreated cutaneous melanoma: median OS 14.3 months on monotherapy (ASCO 2026 update). PRISM-MEL-301 phase 3 with nivolumab in first-line HLA-A*02:01-positive melanoma is enrolling; further trials in ovarian, lung, and endometrial cancer. Requires HLA-A*02:01 (roughly half of European-ancestry patients).

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-07
- Code: IMC-F106C
- Modality: ImmTAC (PRAME TCR × CD3 bispecific)
- Mechanism: Affinity-enhanced TCR binding PRAME peptide-HLA-A*02:01 fused to an anti-CD3 scFv; redirects polyclonal T cells.
- Dosing: Intravenous; Weekly with step-up dosing to 160 µg

## Sources

- Immunocore ASCO 2026 data: https://www.globenewswire.com/news-release/2026/05/31/3303917/0/en/immunocore-presents-updated-phase-1-data-of-brenetafusp-in-patients-with-heavily-pretreated-advanced-melanoma.html

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD3](https://onco.cc/targets/cd3/), [HLA-A](https://onco.cc/targets/hla-a/), [PRAME](https://onco.cc/targets/prame/)
- drugs: [Tebentafusp](https://onco.cc/drugs/tebentafusp/)
- companies: [Immunocore](https://onco.cc/companies/immunocore/)
- trials: [PRISM-MEL-301](https://onco.cc/trials/prism-mel-301/), [Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors](https://onco.cc/trials/nct04262466/)
- terms: [HLA-A*02:01 restriction](https://onco.cc/terms/hla-a02-restriction/), [Uveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class)](https://onco.cc/terms/uveal-melanoma-prognostic-markers/)
- ideas: [TCR therapeutics for non-HLA-A*02 patients](https://onco.cc/ideas/idea-prame-tcr-beyond-a02/)

---
JSON: https://onco.cc/api/v1/entities/brenetafusp.json